Literature DB >> 9249016

Influence of charge differences in the C-terminal part of nisin on antimicrobial activity and signaling capacity.

C Van Kraaij1, E Breukink, H S Rollema, R J Siezen, R A Demel, B De Kruijff, O P Kuipers.   

Abstract

Three mutants of the antibiotic nisin Z, in which the Val32 residue was replaced by a Glu, Lys or Trp residue, were produced and characterized for the purpose of establishing the role of charge differences in the C-terminal part of nisin on antimicrobial activity and signaling properties. 1H-NMR analyses showed that all three mutants harbor an unmodified serine residue at position 33, instead of the usual dehydroalanine. Apparently, the nature of the residue preceding the serine to be dehydrated, strongly affects the efficiency of modification. Cleavage of [Glu32,Ser33]nisin Z by endoproteinase Glu-C yielded [Glu32]nisin Z(1-32)-peptide, which has a net charge difference of -2 relative to wild-type nisin Z. The activity of [Lys32,Ser33]nisin Z against Micrococcus flavus was similar to that of wild-type nisin, while [Trp32,Ser33]nisin Z, [Glu32,Ser33]nisin Z and [Glu32]nisin Z(1-32)-peptide exhibited 3-5-fold reduced activity, indicating that negative charges in the C-terminal part of nisin Z are detrimental for activity. All variants showed significant loss of activity against Streptococcus thermophilus. The potency of the nisin variants to act as signaling molecules for auto-induction of biosynthesis was significantly reduced. To obtain mutant production, extracellular addition of (mutant) nisin Z to the lactococcal expression strains was essential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249016     DOI: 10.1111/j.1432-1033.1997.00114.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  18 in total

1.  Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation.

Authors:  Rick Rink; Jenny Wierenga; Anneke Kuipers; Leon D Kluskens; Arnold J M Driessen; Oscar P Kuipers; Gert N Moll
Journal:  Appl Environ Microbiol       Date:  2007-07-27       Impact factor: 4.792

2.  Isolation, characterization, and heterologous expression of the novel lantibiotic epicidin 280 and analysis of its biosynthetic gene cluster.

Authors:  C Heidrich; U Pag; M Josten; J Metzger; R W Jack; G Bierbaum; G Jung; H G Sahl
Journal:  Appl Environ Microbiol       Date:  1998-09       Impact factor: 4.792

3.  Investigating the importance of charged residues in lantibiotics.

Authors:  Srinivas Suda; Colin Hill; Paul D Cotter; R Paul Ross
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

Review 4.  Bioengineering of the model lantibiotic nisin.

Authors:  Des Field; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Bioengineered       Date:  2015-05-13       Impact factor: 3.269

Review 5.  Pathways of fear and anxiety in dentistry: A review.

Authors:  Ava Elizabeth Carter; Geoff Carter; Mark Boschen; Emad AlShwaimi; Roy George
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

Review 6.  Lantibiotic resistance.

Authors:  Lorraine A Draper; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Microbiol Mol Biol Rev       Date:  2015-06       Impact factor: 11.056

7.  Purification, characterization, and gene sequence of michiganin A, an actagardine-like lantibiotic produced by the tomato pathogen Clavibacter michiganensis subsp. michiganensis.

Authors:  I Holtsmark; D Mantzilas; V G H Eijsink; M B Brurberg
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

8.  LsbB Bacteriocin Interacts with the Third Transmembrane Domain of the YvjB Receptor.

Authors:  Marija Miljkovic; Gordana Uzelac; Nemanja Mirkovic; Giulia Devescovi; Dzung B Diep; Vittorio Venturi; Milan Kojic
Journal:  Appl Environ Microbiol       Date:  2016-08-15       Impact factor: 4.792

Review 9.  Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds.

Authors:  John A McIntosh; Mohamed S Donia; Eric W Schmidt
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

Review 10.  Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.

Authors:  Leif Smith; Jd Hillman
Journal:  Curr Opin Microbiol       Date:  2008-10-24       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.